Emergent BioSolutions (NYSE:EBS) Stock Price Passes Above 200-Day Moving Average of $2.25

Shares of Emergent BioSolutions Inc. (NYSE:EBS) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.25 and traded as high as $2.36. Emergent BioSolutions shares last traded at $2.29, with a volume of 860,990 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “buy” rating and set a $5.00 target price on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

Emergent BioSolutions Trading Up 5.8 %

The stock has a market cap of $119.71 million, a price-to-earnings ratio of -0.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.54 and a current ratio of 1.04. The company’s 50 day simple moving average is $2.43 and its two-hundred day simple moving average is $2.25.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.44). The business had revenue of $276.60 million for the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. During the same quarter in the prior year, the business posted ($0.31) EPS. Research analysts expect that Emergent BioSolutions Inc. will post -13.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in Emergent BioSolutions by 84.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after purchasing an additional 1,312,934 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Emergent BioSolutions by 356.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 834,372 shares of the biopharmaceutical company’s stock valued at $2,002,000 after acquiring an additional 651,480 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Emergent BioSolutions during the 3rd quarter valued at about $712,000. Values First Advisors Inc. lifted its holdings in Emergent BioSolutions by 101.6% during the 4th quarter. Values First Advisors Inc. now owns 307,892 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 155,193 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Emergent BioSolutions by 51.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 453,565 shares of the biopharmaceutical company’s stock worth $1,542,000 after acquiring an additional 153,850 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.